-
Media ReleaseSandoz targets growth opportunities in respiratory and complex generics through acquisition of respiratory device company Coalesce
-
Media ReleaseNovartis presents new findings at ERS reinforcing the efficacy of Enerzair® Breezhaler®, highlighting its digital companion, as well as showcasing commitment to low carbon footprint asthma solutions
-
Media ReleaseNovartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy
-
Media ReleaseNovartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma
-
Media ReleaseNovartis receives CHMP positive opinion for Enerzair® Breezhaler® (QVM149), a potential first-in-class inhaled LABA/LAMA/ICS combination for uncontrolled asthma
-
Media ReleaseNovartis Phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair® Breezhaler® (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthma
-
Media ReleaseNovartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options
-
Media ReleaseNovartis receives EC approval for Enerzair® Breezhaler®, including the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EU
-
Media ReleaseNovartis Phase III IRIDIUM data in Lancet Respiratory Medicine show benefit of Enerzair® Breezhaler® (QVM149), the first-in-class inhaled LABA/LAMA/ICS combination in uncontrolled asthma
-
Media ReleaseNovartis receives EC approval for new Xolair® indication to treat severe chronic rhinosinusitis with nasal polyps
-
Media ReleaseNovartis post hoc analysis shows high-dose Enerzair® Breezhaler® reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings
-
Story
Positive gains are needed to accelerate change for women with lung disease